Home · Health · Oct 16 archive

OB-GYNs Present New Menopause Treatment Data at IMS Congress

· Confirmed

Health Desk

In Short: At the 20th World Congress on Menopause, OB-GYNs presented new data on the treatment of menopause symptoms using fezolinetant (Veoza; Astellas).

LG G5 - Mobile World Congress 2016 (25405564771)
Photo: Kārlis Dambrāns / Wikimedia Commons (CC BY 2.0)

At the 20th World Congress on Menopause, OB-GYNs presented new data on the treatment of menopause symptoms using fezolinetant (Veoza; Astellas). The phase 4 OPTION-VMS real-world study showed statistically significant improvements in vasomotor symptoms and sleep outcomes as early as week 4.

Marla Shapiro, C.M., of the University of Toronto, Canada, and lead author of the OPTION-VMS oral presentation, emphasized the impact of menopause symptoms on women's daily lives, stating, "Hot flushes and night sweats can have a far-reaching impact on women's daily lives, including their sleep, quality of life, and overall well-being."

YouTube — CBS Mornings YouTube

The study highlighted that sleep disturbances, affecting an estimated 40% to 60% of menopausal women, are among the most commonly reported and bothersome symptoms. The data showed improvements in both patient-reported and objectively measured sleep outcomes.

"We could see that there were improvements in all of this at week 4, which was the first time point assessed, and it reassures me when I see objective findings that are consistent with improvements in the patient-reported outcome," Shapiro told Contemporary OB/GYN in a recent interview.

Catherine Cansino, MD, MPH, an obstetrician/gynecologist and co-author of the new guidance, noted, "What's changing is the breadth of options that we now have … And the benefit of that is that we are better equipped to be able to take an individualized approach for patients."

Robert Kauffman, MD, MSCP, another co-author of the guidelines, emphasized hormone therapy as the best option for symptomatic, newly menopausal women within 10 years of the final menstrual period or before the age of 60.

"Hormone therapy is probably the best option for symptomatic, newly menopausal women within 10 years of the final menstrual period or before the age of 60," Kauffman said during a press briefing.

The new guidelines reflect a broader approach to treating menopause symptoms, offering more personalized and effective options for patients.

"If you are going through menopause or are in menopause, and lack of sleep or poor sleep quality is affecting you during the day, talk to your provider," said Kris E. from Norton Healthcare.

A study of 50,000 postmenopausal women found that those who ate more fruits and vegetables had a lower chance of experiencing insomnia, while consuming sugars and carbohydrates increased the risk.

What this adds

The new guidelines and data presented at the IMS Congress reflect a broader approach to treating menopause symptoms, offering more personalized and effective options for patients. This aligns with prior WarpBeat coverage on the updated guidelines by the American College of Obstetricians and Gynecologists.

Background

The new guidelines and approvals reflect a broader approach to treating menopause symptoms and other health issues, offering more personalized and effective options for patients.

The American College of Obstetricians and Gynecologists has updated its guidelines for menopause symptoms, offering broader options including nonhormonal treatments.

What's confirmed

What's still developing

Sources